Author

Sarah K. Wideman

Sarepta Therapeutics (United States)ORCID 0000-0001-7803-9894Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Anna-Dorothea GorkiiD· 1 shared Chama Najmi· 1 shared Delyana Stoeva· 1 shared Guido A. GualdoniiD· 1 shared Heta Telimaa· 1 shared Johannes StöckliD· 1 shared Laxmikant WaliiD· 1 shared Scharon Chou· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Anna-Dorothea GorkiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologyScientific ReportsPeer-reviewedMar 19, 2025

Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models

Sarah K. Wideman, Laxmikant Wali, Vitalii Kovtunyk…·Snezana Radivojev

This study evaluates three 2-deoxylated glucose analogues for their antiviral and anti-inflammatory effects in advanced in vitro airway models, showing they inhibit respiratory viral replication and can be nebulized.

2 citations

experimental assayhost-pathogen & immune response

𝕏 PostBluesky